Introduction
Despite major advances, particularly over the last 20 years, in the development of renal replacement therapy, many patients with renal failure still have a poor quality of life, and a death rate from myocardial infarction comparable to that in non-uraemic patients with a history of previous myocardial infarction.! Abnormalities in haemostasis determined in part by the underlying disease process, the biochemical, acid-base, and endocrine abnormalities associated with chronic renal failure, and the type of renal replacement therapy undertaken, may be factors having a significant role in the development and progression of vascular disease in these patients. Similarly, therapeutic manipulation of haemostasis may either improve or worsen the incidence of vascular thrombotic events. In this respect, the introduction and use of erythropoietin (EPa) in clinical practice in recent years has provided an example of a therapeutic substance which may have both beneficial and adverse effects as a result of its interactions with the haemostatic system. The increase in haemoglobin associated with EPa therapy shortens the bleeding time, and thus reduces the risk of haemorrhage, particularly in haemodialysis patients. Conversely, however, it also appears to significantly enhance the risk of vascular thrombosis.
History of erythropoietin
The concept that circulating humoral factors may stimulate erythropoiesis was originally introduced by Carnot in 1906. 2 He injected relatively small amounts of serum from anaemic rabbits into normal rabbits, and found an increase in red cell count in the normal rabbits. Carnot's experiments, however, were technically flawed, and for many years afterwards others were unable to reproduce his results. Definite confirmation of the existence of EPa was produced by Erslev.! when he injected large quantities of anaemic rabbit serum into normal rabbits and produced a significant rise in red cell count. Subsequent investigations, wherein various organs were removed from laboratory animals, indicated that the main site of EPO production in adult life was in the kidney," with 10% of EPO production being retained in the Iiver.> EPO, which is present in very low concentrations in plasma, was initially purified from the plasma of large numbers of anaemic sheep (over 300 sheep per 10 mg EPO),6 and then from the urine (approximately 2500 litres) of patients with aplastic anaemia." Human EPO is a glycoprotein which consists of 165 amino acids, and has a molecular weight of approximately 34 000 daltons. The purified hormone was subjected to a detailed analysis of its amino acid content, to allow determination of the gene which coded for it, by using recombinant DNA techniques.s-? The gene was then cloned in cultured mammalian cells (Chinese hamster ovary cells) to produce larger quantities sufficient for use in clinical practice.
Anaemia in chronic renal failure
Anaemia in chronic renal failure is multifactorial in origin. The factors involved include: lack of EPO production; haemolysis and shortened red cell lifespan; uraemic inhibitors of marrow function (e.g. aluminium); marrow fibrosis (as in severe hyperparathyriodism); and intermittent blood loss (e.g. during dialysis or from the gastrointestinal tract) especially with repeated heparinization during haemodialysis. The fact that patients with polycystic kidney disease are able to maintain a high haemoglobin in a uraemic milIeu, in addition to the dramatic haemoglobin responses observed with exogenously applied EPO, would tend to indicate that lack of, and/or defective control of, EPO production from diseased kidneys is the primary cause of anaemia in these patients.
Erythropoietin, haemostasls and thrombosis
In the initial trials of EPO in haemodialysis patients, a relatively high incidence of thrombotic events occurred relative to the numbers of patients treated. For example, in Winearls' study of 10 patients, two had episodes of fistula thrombosis. to Similarly in an Italian trial involving 14 patients, two patients had fistula thrombosis and, in addition, one patient developed cerebral ischaemia.t! Larger multicentre trials determined an incidence of vascular access thrombosis of approximately 14% ,12,13 most episodes occurring in association with a significant increase in haematocrit but, interestingly, usually within the first six months of therapy. A well-designed placebocontrolled Canadian study also showed a significantly higher incidence of fistula thrombosis, particularly at higher EPO doses.> However, any direct effect of EPO on coagulation could not be inferred from this study, since the patients on higher EPO doses also had higher haematocrits. In contrast, however, a large American multicentre trial consisting of over 300 patients could not detect a significant increase in vascular thrombosis in patients receiving EPO. 15 Hence any significant effect of EPO on thrombosis in clinical practice still requires further clarification.
As well as the possible effects of EPO on blood coagulation and thrombosis, its use also has a well-documented association with hypertension and seizures. Correction of the anaemic state associated with chronic renal failure reduces, and thus 'normalizes', cardiac output,I6--18 improves ventricular function,17,19,20 and reverses hypoxic vasodilaticn.s! Similarly whole blood viscosity approaches norma1. 22 ,23 Thus a rise in peripheral vascular resistance, potentially leading to hypertension, has been observed by some investigators,18,24 but not by others. 17, 19 Circulating vasoactive substances, such as atrial natriuretic peptide, renin, angiotensin II, adrenaline, noradrenaline, dopamine and endothelin, in general do not appear to change with EPO,25,26 although one study found renin and aldosterone to decrease in normotensive patients following EPO therapy.F Although the binding of endotheliumderived relaxing factor by haemoglobin has been suggested as a possible contributory factor to the increased peripheral vascular resistance following EPO,28 this has been disputed by others-? who have shown that binding of endothelium-derived relaxing factor is maximal at a haemoglobin concentration of 4 g/dl, which is well below the range of changes seen during EPO therapy. It is possible that an imbalance between cardiac and peripheral vascular haemodynamics, and changes in blood coagulation and rheology, in the presence of the abnormal vasculature characteristic of the uraemic state,3G-32 may determine the development of hypertension, seizures and thrombosis in dialysis patients receiving EPO, since the use of EPO in non-uraemic patients for autologous preoperative blood transfusion does not appear to be associated with similar problerns.P Not all adverse events in EPO-treated dialysis patients can, however, be attributed to the change in haemoglobin alone. In the European multicentre studies, some episodes of fistula thrombosis and seizures occurred at haemoglobin levels which were not significantly greater than those observed following previous blood transfusion. l1 -13 Similarly, seizures were in some cases observed in the absence of hypertension.P or the blood pressure observed at the time of the event was lower than that normally associated with hypertensive encephalopathy. 34 These observations suggested that mechanisms other than the haemodynamic and rheological effects of a changing haemoglobin may be responsible for some of EPO's side effects. In this respect, some studies have shown transient changes in platelet aggregation and platelet intracellular free calcium concentration.v and in protein C and protein S levels,36,37 thrombin-antithrombin III complex levels,37,38 and prostacyclin stimulating factor>? during the initial months of EPO therapy, which could indicate that microvascular factors may also be of importance.
Further evidence for more 'direct' effects of EPO comes from the studies of Heidenreich et al. 39 who demonstrated a calcium-dependent vasopressor effect of high concentrations of EPO on rat renal arterioles in vitro. These investigators also showed that EPO increases cytosolic free calcium concentration in cultured vascular smooth muscle cells in a dose-dependent manner in vitro,40 and confirmed the findings of Van Geet et al. 41 of increased platelet intracellular free calcium concentration following EPO, In this study, however, the effect was independent of extracellular calcium concentration, thus implying that the calcium had been mobilized from intracellular stores. Certainly, EPO has been shown to stimulate calcium flux in cells, primarily from intracellular stores.sand changes in intracellular calcium have been independently linked to both hypertension-a and haemostasis.s-t No correlation, however, has yet been demonstrated between absolute blood pressure level and platelet intracellular free calcium, or changes in these parameters during EPO therapy.s> Similarly, Bund et al. 46 were unable to confirm the direct vasopressor effect of EPO described by Heidenreich et al. 39 using human subcutaneous arterioles.
On the other hand, the presence of EPO receptors on endothelial cells which may proliferate in a dose-dependent fashion in response to EPO,47 in addition to the observations of increased blood pressure in exercised men,48 and normotensive laboratory rats 49 following EPO, would tend to support the evidence for independent effects of EPO on vascular function. Certainly, similar changes were not observed in normal men after transfusion therapy.w or in dialysis patients after transfusions.v iron-dextran therapy.ss or transplantation,53
In the following sections, the results of studies which have specifically investigated haemostasis and thrombosis in dialysis patients receiving EPO are summarized.
Effect of erythropoietin on platelet function
In vitro studies have shown that EPO potentiates the growth of megakaryocyte colonyforming units from normal human marrow in leucocyte-conditioned culture medium. The mechanism of this effect is unknown, and could be due to either stem cell recruitment, induction of cell proliferation, or sensitization of the cells o another growth factor.>' In vivo, some 64 In all studies, however, the use of EPO has been associated with a significant reduction in the bleeding time, suggesting an improvement in platelet function be it either directly due to EPO, or indirectly as a consequence of the increased red cell mass.
Several studies have demonstrated enhanced platelet adhesion following EPO therapy. In an early study in seven patients, Moia et al. 6O observed increased platelet adhension to umbilical artery subendothelium, which correlated with both the increase in haematocrit and the reduction in bleeding time. They proposed that the extra red cells could mediate this effect by displacing the centrally flowing platelets towards the vessel walls. These findings were confirmed by Akizawa et al. 58 who also demonstrated that platelet adhesion was only improved in those patients who had shortened bleeding times with EPO therapy. Hence, factors other than the reduced haematocrit were able to impair platelet adhesion in uraemia. However, a further study by Zwaginga et al., 61 in which platelet adhesion to sprayed collagen surfaces or endothelium was assessed using platelet suspensions at a fixed haematocrit, suggested that the haemotocrit was not at all important for the effect of EPO on platelet adhesion. These investigators proposed the presence of a circulating inhibitor of platelet adhesion, which was overcome in those EPO-treated patients with shortened bleeding times, either as a consequence of the increased red cell mass binding the inhibitor, or alternatively reducing its production due to improved tissue oxygenation. The study of Cases et al. 59 also demonstrated a haematocrit-independent improvement in platelet adhesion to vascular subendothelium, an effect which they attributed, however, to an EPOmediated release of younger, more metabolically active platelets from the bone marrow.
As well as changes in platelet adhesion, platelet aggregation (measured in platelet-rich plasma) may also improve following EPO. The studies of Van Geet et al. 35 ,41 (ADP, ristocetin, and collagen-induced aggregation), Huraib et al. 57 (ADP, arachidonic acid, collagen, ristocetin and adrenaline-induced aggregation), Zwaginga Platelet aggregation measured in whole blood also improves following EPO. The use of a whole blood t~chnique is perhaps more appropriate in the setting of EPO therapy since it permits interactions between platelets and other blood cells in particular red blood cells, to occur. Using this technique it has been shown that correction of anaemia with EPO produces enhanced spontaneous, and to a lesser extent collagen-and ADP-induced platelet aggregation.37,62,63 The changes in spontaneous platelet aggregation are the most marked, the levels observed following EPO thera~y being significantly higher than in normals ( Figure 1) .37,62 This may have clinical relevance, since in other patient groups, (e.g. P?stmyocardial infarction and peripheral vascular disease) spontaneous platelet hyperaggregability in vitro has been associated with a risk of thrombosis in vivo. 65 ,66 The changes in spontaneous platelet aggregation are reversible when E~O is withd~awn, and a close relationship with haematocnt has been demonstrated within individual patients. 37,62,67 Similarly spontaneous platelet aggregation is also enhanced during the course of a dialysis session following EP068 (Figure 2) , a factor which could be relevant to the increased incidence of extracorporeal circuit thrombosis whi~h is associated with this therapy.ts Red c.ells may influence platelet interactions, by releasing proaggregatory substances, in particular ADP, both in the immediate vicinity of platelet contact as well as into the surrounding medium,69,7o and by physically channelling the platelets towards the endothelial surface."! In renal failure, these mechanisms could be enhanced owing to the red cells being less deformable,n and having shortened lifespans.P thus with increased membrane fragility, haemolysis, and presumably increased release of platelet activating substances.
Platelet arachidonic acid metabolites (thromboxane B 2 and prostaglandin E 2), the release of platelet factor 4 and l3-thromboglobulin, and platelet nucleotide contents (ADP, ATP) do not appear to change following EPO. 56, 58, 68, 74 Factor VIII von Willebrand factor (FVIlIvWF) is necessary for platelet-platelet and platelet-endothelial interactions.P It is synthesized and stored by vascular endothelium, and is released in the presence of endothelial damage. For this reason, in other disease states it has been used as a marker for monitoring the progression of vasculitis'" which has certain features (e.g. chronic inflammatory cell infiltration) in common with the uraemic vasculopathy. Levels of FVIIlvWF were found to increase in some studies following EPO therapy,37,57,58 but not significantly in others. 55 structure, however, was unchanged. 58 One study who subsequently developed fistula thrombosis.t? showed the levels of FVIIlvWF to increase with It is possible, therefore, that any increase in haematocrit towards those levels observed in FVIIIvWF could represent endothelial damage non-EPO-treated dialysis patients with intrinsi-consequent upon a higher red cell mass in a cally higher haemoglobins, and in addition found more vasoconstricted but abnormally structured FVIIlvWF to be particularly high in those patients vasculature. however, influence the enhancement of platelet adhesion and aggregation observed during EPO therapy.
Effect of erythropoietin on blood coagulation and fibrinolysis
Most studies have been unable to demonstrate any change in fibrinogen or other coagulation factors during the course of EPO therapy. Two studies, however, did observe increases in fibrinogen,37,57 and one study an increase in factor VIII coagulant activity, 57 Fibrinogen is an important determinant of plasma viscosity."? In addition, high levels have been associated with enhanced platelet aggregation, and are a risk factor for mortality from myocardial infarction and stroke.?" Koppensteiner et alJ? noted increased baseline fibrinogen levels in those patients who later developed vascular access thrombosis during EPO therapy, Similarly, in a further study, fibronogen levels were found to increase with EPO towards those levels observed in non-EPO-treated dialysis patients with intrinsically high haemoglobins, and the levels were often high when measured just prior to a thrombotic event.J7 Since, however, a high haematocrit in association with high fibrinogen levels has been linked to the development of hypertension,80 such a combination in dialysis patients may potentially increase cardiovascular morbidity.
Inhibitors of coagulation (e.g. antithrombin III) do not appear to change during EPO therapy. 36, 55 On the other hand, Macdougall et al. 36 demonstrated a transient but significant decrease in protein C and protein S levels occurring approximately three months after commencement of EPO therapy and regardless of route of EPO administration. This change was not sustained, protein C and protein S returning to pre-EPO levels after six months of therapy, These observations were confirmed in a further study.t? which also demonstrated a transient increase in thrombin-antithrombin III complex, a marker of the activation of coagulation.s! and a transient decrease in prostacyc1in stimulating factor, a plasma factor which controls the release of endothelial prostacyclin and thus inhibits platelet aggregation. Interestingly the changes in platelet aggregation in the studies of Van Geet et al, 35.41 were also transient in nature, again showing a maximal change at approximately three months.
The mechanisms underlying such changes are unknown, but they may be of some clinical relevance, since in large clinical studies of EPO the incidence of adverse events, especially seizures but also vascular access thrombosis and hypertension, was greater during the initial months of therapy, the incidence decreasing with time despite continuation of EPO and maintenance of even higher haemoglobin concentrations. 12, 13, 15, 82 Perhaps the most likely explanation is that there is a transient imbalance between the changes in cardiac output, and in peripheral vascular resistance in association with the rise in haemoglobin during EPO therapy, This could lead to elevated blood pressure with endothelial damage, enhanced coagulation, release of vasoactive factors, and changes in vascular permeability, manifesting in susceptible patients as severe hypertension and seizures, or as thrombosis. A direct effect of EPO seems less likely, since there was no apparent effect of route of EPO administration or EPO dose,36,37 and in other larger clinical studies looking at adverse events with EPO there was no definite association between the events and EPO dose. 12,13.15 Markers of fibrinolysis such as fibrinopeptide A61 and D-dimer37.55.56 do not appear to change with EPO, although patients with renal failure tend to have enhanced fibrinolysis,37,83,84 which may serve to compensate for some of the procoagulatory effects potentially associated with EPO therapy.
Effect of erythropoietin on blood rheology
Treatment with EPO improves tissue oxygenation, and thus reverses to some extent the hyperdynamic circulatory state associated with chronic anaemia. Changes in cardiac output, blood viscosity, and peripheral vascular resistance may take place, and potentially alter the flow of blood to the peripheries. Similarly, the development of hypertension may also lead to endothelial damage and thus promote atherogenesis.s> Some studies have demonstrated a reduction in blood flow through the leg after EPO,24 whereas others have found no change.w Several studies have demonstrated increased whole blood viscosity following EPO under both high and low shear conditions,22,36 but predominantly at low shear rates. The levels observed following EPO either approached 22,36 or attained> those levels observed in normal individuals depending upon the final level of hae~oglobin ac~ieved. Erythrocyte aggregation, which predominantly influences blood viscosity under low shear conditions was also found to increase after EPO. 79 The;e is conflicting evidence from the different studies with regard to changes in erythrocyte deformability. Erythrocyte deformability is an important determinant of blood viscosity un~er high shear conditions, and is g~nerally con~ld ered to be reduced in the uraemic state.P Using filtration techniques, however, two studies in peritoneal dialysis patients, 63 89 usmg micropipette techniques. These investigators found that erythrocyte deformability was less than normal before EPO, and improved to levels comparable to normals following EPO. Their find.ings. co~ld~o.t be attributed to either changes in dialysis efficiency or red cell age, and it was therefore pr?posed~hat EPO might improve cytoskeletal protem function, Certainly, the fact that wh~le blood viscosity do~s not exceed normal following EPO would be m keeping with an improvement in an abnormally low pretreatment erythrocyte deformability.
Effect of erythropoietin on white blood cells
There is now a substantial body of epidemiological, clinica~, and experimental e~i dence linking the white blood cell, and in particular the granulocyte, with the pathogenesis of atherosclerotic disease and its sequelae.P? White blood cells may, by virtue of their physi~al size and shape, their capacity to release va~o~ctlve and prothrombotic substances, and their m~er action with other blood components, potentiate coagulation and thrombosis. A rise in white c~ll count during EPO therapy has been observed m some studies,12.1S.63 but not in others. 13.37.91 In all studies however, the white cell count has always remain~d within the normal range. Differential white cell count did not change in Bommer et al.'s study,"! whereas in Eschbach et al.'s study'> a statistically significant increase in the percentage of monocytes was seen after six months of therapy at maintenance haemoglobin levels. The relevance of this observation is unclear. Granulocytes are large relative to capillaries, hence any increase in aggregability or hardness may lead to physical obstruction, and thus tissue ischaemia and damage. Dialysis-dependent patients have granulocytes which are more aggregable than normal in vitro 92 but this does not appear to change with EPO therapy.37.63
Conclusion
In conclusion, patients receiving renal replacement therapy have abnormalities affecting aU aspects of haemostasis, for example in platelet adhesion and aggregation, in blood coagulation and fibrinolysis, and in blood vessel walls. These effects are probably determined by the underlying renal disease, the uraemic state and the form of renal replacement therapy undertaken. Although dialysis patients have increased morbidity and mortality from vascular causes, it is possible that, in the pre-EPO era, the presence of anaemia and its associated bleeding diathesis afforded some protection against such vascular damage. EPO therapy has had a major impact on the quality of life of dialysis patients. There are, however, documented changes in platelet function, fibrinogen and FVIIIvWF (a marker of endothelial damage) in patients receiving EPO, which appear to be at least partially a consequence of the increased red cell mass, but which could potentially enhance the risk of vascular thrombotic events. Long-term epidemiological studies will soon determine if correction of anaemia in dialysis patients significantly influences the death rate from vascular disease. The use of antiplatelet therapy may therefore be helpful in some patients, and less hazardous now that many of them will no longer have a significant bleeding tendency, in order to protect against such effects. Certainly aspirin has been shown to reverse the changes in spontaneous platelet aggregation associated with EPO therapy.s? and may also prevent the loss of dialysis efficiency which can be associated with the maintenance of a higher haematocrit. 93 
